Outcomes of post-exposure vaccination by modified vaccinia Ankara to prevent mpox (formerly monkeypox): a retrospective observational study in Lyon,France, June to August 2022 |
| |
| Authors: | Yanis Merad,Alexandre Gaymard,Laurent Cotte,Thomas Perpoint,Dulce Alfaiate,Matthieu Godinot,Agathe Becker,Olivier Cannesson,Anne-Sophie Batalla,Fatima Oria-Yassir,Sophie Landré ,Florence Morfin,Maude Bouscambert,Florent Valour,Florence Ader,Anne Conrad |
| |
| Abstract: | ![]()
Modified vaccinia virus Ankara vaccine (MVA-BN; Bavarian Nordic) is recommended to contacts of mpox cases up to 14 days post-exposure but the effectiveness of this strategy is unknown. Among 108 adults (≥ 18 years old) who received one dose of MVA-BN after exposure to mpox, 11 (10%) cases of breakthrough mpox were observed. Sexual exposure was associated with the risk of breakthrough mpox (p = 0.0179). Samples taken from vaccinated breakthrough mpox cases had similar rates of infectious virus isolation than unvaccinated mpox cases. |
| |
| Keywords: | Modified Vaccinia Virus Ankara Monkeypox Mpox Post-exposure Vaccination |
|
|
